A growing body of research is reshaping the treatment landscape for diffuse large B-cell lymphoma (DLBCL), with emerging strategies aimed at improving outcomes across patient populations, from elderly or frail individuals to those with biologically defined subtypes. Recent studies highlight how both bispecific antibodies and novel targeted agents are helping to fill longstanding gaps in care.
One key area of progress is the development of chemotherapy-free approaches for patients who are unable to tolerate standard regimens. In the phase 2 MorningSun study, the CD20×CD3 bispecific antibody mosunetuzumab was evaluated as first-line therapy in elderly or chemotherapy-ineligible patients with previously untreated DLBCL.1 The study population, with a median age of 83 years, reflects a group often underrepresented in clinical trials and with limited treatment options.
Despite these challenges, mosunetuzumab demonstrated meaningful clinical activity. The overall response rate reached 73.5%, including a complete response rate of 59.2%. Survival outcomes were also encouraging, with 12-month progression-free survival of 66.0% (95% CI, 49.9-78.0) and overall survival of 73.8% (95% CI, 58.4-84.2). In addition to these efficacy findings, more than half of patients experienced clinically meaningful improvements in lymphoma-related symptoms, underscoring the potential quality-of-life benefits of a chemotherapy-free approach.1
The safety profile was consistent with expectations for bispecific antibodies and was generally manageable in this older population. Cytokine release syndrome occurred infrequently (12.2%) and was low grade, whereas injection site reactions were common (53.1%) but mild. Although infections (53.1%) and higher-grade adverse events were observed (69.4%), these were considered manageable, supporting the feasibility of outpatient administration in a population with significant baseline vulnerability.1
In parallel, early-phase and ongoing trials are exploring targeted therapies designed to address specific biologic drivers of lymphoma. One such approach involves ARV-393, an oral PROTAC molecule that degrades BCL6, a key oncogenic transcription factor in germinal center–derived lymphomas.2 In a first-in-human phase 1 study, ARV-393 is being evaluated both as monotherapy and in combination with glofitamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and DLBCL.
This strategy reflects a shift toward exploiting tumor biology at a mechanistic level. Preclinical data have shown that BCL6 degradation can inhibit tumor growth and may enhance the activity of bispecific antibodies, providing the rationale for combination approaches. The ongoing study is assessing safety, pharmacologic properties, and early signals of antitumor activity, with the goal of establishing dosing for further development.2
Another investigational effort is evaluating zilovertamab vedotin, a ROR1-directed antibody–drug conjugate, in the frontline setting for patients with germinal center B-cell–like (GCB) DLBCL.3 The randomized phase 2 waveLINE-011 trial is comparing zilovertamab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) with polatuzumab vedotin plus R-CHP, the current standard approach. This trial addresses a key unmet need, as outcomes with existing frontline regimens remain variable in GCB DLBCL despite advances in treatment.3
Together, these studies highlight a broader shift in DLBCL management. For older patients, bispecific antibodies such as mosunetuzumab offer the promise of effective, less toxic, chemotherapy-free regimens. At the same time, targeted therapies aimed at specific molecular pathways—such as BCL6 and ROR1—are being integrated into both relapsed and frontline treatment settings in an effort to improve efficacy and tailor therapy more precisely.
As these approaches continue to evolve, they signal a transition toward more personalized and biologically driven care in lymphoma, with the potential to expand treatment options and improve outcomes across diverse patient populations.